Evidence map›Paper›PMID 39702290›Full record

ArticleEpigenetics & chromatin2024

Dissecting the Kaiso binding profile in clear renal cancer cells.

Alexey Starshin, Pavel Abramov, Yaroslava Lobanova, Fedor Sharko, Galina Filonova, Dmitry Kaluzhny, Daria Kaplun, Igor Deyev, Alexander Mazur, Egor Prokhortchou and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Epigenetics & chromatin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Alexey StarshinFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Pavel AbramovFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Yaroslava LobanovaFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Fedor SharkoFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Galina FilonovaFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Dmitry KaluzhnyEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
Daria KaplunFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Igor DeyevShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia.
Alexander MazurFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Egor ProkhortchouFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia.
Svetlana ZheniloFederal Research Centre, Fundamentals of Biotechnology», Russian Academy of Sciences, 119071, Moscow, Russia. szhenilo@gmail.com.

Funding

Ministry of Science and Higher Education of the Russian Federation АААА-А20-120121790092-6Russian Science Foundation 19-74-30026
6 · The paper itself

Abstract

backgroundThere has been a notable increase in interest in the transcriptional regulator Kaiso, which has been linked to the regulation of clonal hematopoiesis, myelodysplastic syndrome, and tumorigenesis. Nevertheless, there are no consistent data on the binding sites of Kaiso in vivo in the genome. Previous ChIP-seq analyses for Kaiso contradicted the accumulated data of Kaiso binding sites obtained in vitro. Here, we studied this discrepancy by characterizing the distribution profile of Kaiso binding sites in Caki-1 cells using Kaiso-deficient cells as a negative control, and compared its pattern on chromatin with that in lymphoblastoid cell lines.

resultsWe employed Caki-1 kidney carcinoma cells and their derivative, which lacks the Kaiso gene, as a model system to identify the genomic targets of Kaiso. The principal binding motifs for Kaiso are CGCG and CTGCNAT, with 60% of all binding sites containing both sequences. The significance of methyl-DNA binding activity was confirmed through examination of the genomic distribution of the E535A mutant variant of Kaiso, which cannot bind methylated DNA in vitro but is able to interact with CTGCNA sequences. Our findings indicate that Kaiso is present at CpG islands with a preference for methylated ones. We identified Kaiso target genes whose methylation and transcription are dependent on its expression. Furthermore, Kaiso binding sites are enriched at CpG islands, with partial methylation at the 5' and/or 3' boundaries. We discovered CpG islands exhibiting wave-like methylation patterns, with Kaiso detected in the majority of these areas. Similar data were obtained in other cell lines.

conclusionThe present study delineates the genomic distribution of Kaiso in cancer cells, confirming its role as a factor with a complex mode of DNA binding and a strong association with CpG islands, particularly with methylated and eroded CpG islands, revealing a new potential Kaiso target gene-SQSTM1, involved in differentiation of acute myeloid leukemia cells. Furthermore, we discovered the existence of a new class of CpG islands characterized by wave-like DNA methylation.

Indexed as

DNA MethylationKidney NeoplasmsTranscription FactorsBinding SitesCarcinoma, Renal CellCell Line, TumorChromatinCpG IslandsHumansNucleotide MotifsProtein BindingChromatinTranscription FactorsZBTB33 protein, humanCpG islands erosionDNA methylationKaisoMethyl-DNA binding proteinsSQSTM1

Identifiers

PMID39702290
PMCPMC11657142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.